162 related articles for article (PubMed ID: 17465260)
21. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.
Gårdmark T; Carringer M; Beckman E; Malmström PU;
Urology; 2005 Sep; 66(3):527-30. PubMed ID: 16140071
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic study to optimize the intravesical administration of gemcitabine.
Gontero P; Cattel L; Paone TC; Milla P; Berta G; Fiorito C; Carbone F; Medana C; Tizzani A
BJU Int; 2010 Dec; 106(11):1652-6. PubMed ID: 20590553
[TBL] [Abstract][Full Text] [Related]
23. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs.
Witjes JA; Vriesema JL; van der Heijden AG; Peters GJ; Schalken JA
Eur Urol; 2003 Nov; 44(5):615-9. PubMed ID: 14572765
[TBL] [Abstract][Full Text] [Related]
25. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder.
Maffezzini M; Campodonico F; Canepa G; Capponi G; Fontana V
Eur Urol; 2007 Apr; 51(4):956-61. PubMed ID: 17027141
[TBL] [Abstract][Full Text] [Related]
26. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.
Madeb R; Golijanin D; Noyes K; Fisher S; Stephenson JJ; Long SR; Knopf J; Lyman GH; Messing EM
Cancer; 2009 Jun; 115(12):2660-70. PubMed ID: 19455607
[TBL] [Abstract][Full Text] [Related]
27. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
[TBL] [Abstract][Full Text] [Related]
28. Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review.
Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
Investig Clin Urol; 2021 Nov; 62(6):623-630. PubMed ID: 34729962
[TBL] [Abstract][Full Text] [Related]
29. Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: evaluation of tolerance.
Morabito F; Rossi R; Graziano ME; Ferrando U; Lancini V; Cretarola E; Conti G; Luporini AC; Muto G; Castelli E; D'Urso L; Razionale P; Lissoni G; Simone M; Francesca F; Sommariva M; Casu M; Hurle R
Arch Ital Urol Androl; 2006 Mar; 78(1):1-4. PubMed ID: 16752879
[TBL] [Abstract][Full Text] [Related]
30. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.
Bartoletti R; Cai T; Gacci M; Giubilei G; Viggiani F; Santelli G; Repetti F; Nerozzi S; Ghezzi P; Sisani M;
Urology; 2005 Oct; 66(4):726-31. PubMed ID: 16230125
[TBL] [Abstract][Full Text] [Related]
31. Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failure.
Allchorne P; Lamb BW; Kinsella J; Shamash J; Green JS
Urol Nurs; 2014; 34(2):95-9. PubMed ID: 24919248
[TBL] [Abstract][Full Text] [Related]
32. Intravesical gemcitabine: an update of clinical results.
Hendricksen K; Witjes JA
Curr Opin Urol; 2006 Sep; 16(5):361-6. PubMed ID: 16905983
[TBL] [Abstract][Full Text] [Related]
33. [Single, immediate postoperative intra-vesical instillation (SI) compared to a single preoperative intra-vesical instillation of mitomycin C in non-muscle invasive bladder cancer (NMIBC). Phase II randomized trial].
Breton J; Bernardeau S; Vallée M; Pillot P; Lebacle C; Delpech PO; Charles T; Biscans C; Vallat A; Pfister C; Irani J
Prog Urol; 2021 Feb; 31(2):63-70. PubMed ID: 32891506
[TBL] [Abstract][Full Text] [Related]
34. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer.
Brocks CP; Büttner H; Böhle A
J Urol; 2005 Sep; 174(3):1115-8. PubMed ID: 16094076
[TBL] [Abstract][Full Text] [Related]
36. RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
Yang Z; Fu B; Zhou L; Xu J; Hao P; Fang Z
BMC Urol; 2019 Jul; 19(1):69. PubMed ID: 31340801
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapy].
Kohjimoto Y; Iba A; Shintani Y; Uekado Y; Shinka T
Hinyokika Kiyo; 2005 Aug; 51(8):533-8. PubMed ID: 16164269
[TBL] [Abstract][Full Text] [Related]
38. The effects of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin in superficial bladder cancer: a preliminary study.
Cho DY; Bae JH; Moon DG; Cheon J; Lee JG; Kim JJ; Yoon DK; Park HS
J Int Med Res; 2009; 37(6):1823-30. PubMed ID: 20146880
[TBL] [Abstract][Full Text] [Related]
39. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
40. Perioperative chemotherapy: when to use it, what to use, and why.
Johnson DC; Pruthi RS; Woods ME
Urol Clin North Am; 2013 May; 40(2):183-95. PubMed ID: 23540777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]